Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

Abstract

Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versus-malignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors. Bone Marrow Transplantation (2001) 27, Suppl. 2, S13–S22.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Thomas ED . Marrow transplantation for malignant diseases J Clin Oncol 1983 1: 517–531

    CAS  PubMed  Google Scholar 

  2. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts New Engl J Med 1979 300: 1068–1073

    CAS  PubMed  Google Scholar 

  3. Weiden PL, Sullivan KM, Flournoy N et al., the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation New Engl J Med 1981 304: 1529–1532

    CAS  PubMed  Google Scholar 

  4. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms New Engl J Med 1989 320: 828–834

    CAS  PubMed  Google Scholar 

  5. Gale RP, Champlin RE . How does bone marrow transplantation cure leukemia? Lancet 1984 2: 28–30

    CAS  PubMed  Google Scholar 

  6. Gale RP, Horowitz MM, Ash RC et al. Identical-twin bone marrow transplants for leukemia Ann Intern Med 1994 120: 646–652

    CAS  PubMed  Google Scholar 

  7. Fefer A, Cheever MA, Greeberg PD . Identical-twin (syngeneic) marrow transplantation for hematologic cancers J Natl Cancer Inst 1986 76: 1269–1271

    CAS  PubMed  Google Scholar 

  8. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia Blood 1991 78: 2120–2130

    CAS  PubMed  Google Scholar 

  9. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555–562

    CAS  PubMed  Google Scholar 

  10. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 1995 86: 2041–2050

    CAS  Google Scholar 

  11. Van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse Blood 1994 83: 3377–3383

    CAS  PubMed  Google Scholar 

  12. Cullis JO, Jiang YZ, Schwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation Blood 1992 79: 1379–1381

    CAS  PubMed  Google Scholar 

  13. Antin JH . Graft-versus-leukemia: no longer an epiphenomenon Blood 1993 82: 2273–2277

    CAS  PubMed  Google Scholar 

  14. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose Blood 1993 82: 2310–2318

    CAS  PubMed  Google Scholar 

  15. Hoffmann T, Theobald M, Bunjes D et al. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells Bone Marrow Transplant 1993 12: 1–8

    CAS  PubMed  Google Scholar 

  16. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444

    PubMed  Google Scholar 

  17. Giralt SA, Champlin RE . Leukemia relapse after allogeneic bone marrow transplantation: a review Blood 1994 84: 3603–3612

    CAS  PubMed  Google Scholar 

  18. Keil F, Haas OA, Fritsch G et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia Blood 1997 89: 3113–3117

    CAS  PubMed  Google Scholar 

  19. Faber LM, Van der Hoeven J, Goulmy E et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes J Clin Invest 1995 96: 877–883

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Jiang Y-Z, Kanfer EJ, Macdonald D et al. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells Bone Marrow Transplant 1991 8: 253–258

    CAS  PubMed  Google Scholar 

  21. Sosman JA, Oettel KR, Smith SD et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells Blood 1990 75: 2005–2016

    CAS  PubMed  Google Scholar 

  22. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 1999 94: 3234–3241

    CAS  PubMed  Google Scholar 

  23. Goulmy E, Voogt P, Van Els C et al. The role of minor histocompatibility antigens in GVHD and rejection: a mini-review Bone Marrow Transplant 1991 7 (Suppl. 1): 49–51

    Google Scholar 

  24. Falkenburg JHF, Goselink HM, Van der Harst D et al. Growth inhibition of clonogeneic leukemic precursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes J Exp Med 1991 174: 27–33

    CAS  PubMed  Google Scholar 

  25. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens Blood 1999 93: 2336–2341

    CAS  PubMed  Google Scholar 

  26. Bonnett D, Warren EH, Greenberg PD et al. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells Proc Natl Acad Sci USA 1999 96: 8639–8644

    Google Scholar 

  27. Warren EH, Greenberg PD, Riddell SR . Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution Blood 1998 91: 2197–2207

    CAS  PubMed  Google Scholar 

  28. Clave E, Molldrem J, Hensel N et al. Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia J Immunother 1999 22: 1–6

    CAS  PubMed  Google Scholar 

  29. Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units Blood 1997 90: 2529–2534

    CAS  PubMed  Google Scholar 

  30. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood 1996 88: 2450–2457

    CAS  PubMed  Google Scholar 

  31. Molldrem JJ, Lee PP, Wang CQ et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia Cancer Res 1999 59: 2675–2681

    CAS  PubMed  Google Scholar 

  32. Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide Blood 2000 95: 286–293

    CAS  PubMed  Google Scholar 

  33. Korngold R, Sprent J . T cell subsets and graft-versus-host disease Transplantation 1987 44: 335–339

    CAS  PubMed  Google Scholar 

  34. Korngold R, Sprent J . Variable capacity of L3 T4 + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice J Exp Med 1987 165: 52–64

    Google Scholar 

  35. Ferrara JLM, Deeg HJ . Mechanisms of disease: graft-versus-host disease New Engl J Med 1991 324: 667–674

    CAS  PubMed  Google Scholar 

  36. Ferrara JLM, Abhyankar S, Gilliland DG . Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1 Transplant Proc 1993 25: 1216–1217

    CAS  PubMed  Google Scholar 

  37. Ferrara JLM, Krenger W . Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines Transf Med Rev 1998 12: 1–17

    CAS  Google Scholar 

  38. Truitt RL, Atasoylu AA . Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow Bone Marrow Transplant 1991 8: 51–58

    CAS  PubMed  Google Scholar 

  39. Okunewick JP, Kociban DL, Machen LL, Buffo MJ . The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia Bone Marrow Transplant 1991 8: 445–452

    CAS  PubMed  Google Scholar 

  40. Okunewick JP, Kociban DL, Machen LL, Buffo MJ . Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia Bone Marrow Transplant 1995 16: 451–456

    CAS  PubMed  Google Scholar 

  41. Faber LM, Van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF . Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia J Exp Med 1992 176: 1283–1289

    CAS  PubMed  Google Scholar 

  42. Jiang Y-Z, Barrett AJ . Cellular and cytokine mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogeneous leukemia Exp Hematol 1995 23: 1167–1172

    CAS  PubMed  Google Scholar 

  43. Jiang YZ, Mavroudis D, Dermime S et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen Br J Haematol 1996 93: 606–612

    CAS  PubMed  Google Scholar 

  44. Van der Harst D, Goulmy E, Falkenburg JHF et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones Blood 1994 83: 1060–1066

    CAS  PubMed  Google Scholar 

  45. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA . Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation Ann Hematol 1997 74: 1–6

    CAS  PubMed  Google Scholar 

  46. Zeis M, Uharek L, Glass B et al. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice Transplantation 1995 59: 1734–1736

    CAS  PubMed  Google Scholar 

  47. Glass B, Uharek L, Zeis M et al. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia Br J Haematol 1996 93: 412–420

    CAS  PubMed  Google Scholar 

  48. Ribas A, Bui LA, Butterfield LH et al. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities Anticancer Res 1999 19: 1165–1170

    CAS  PubMed  Google Scholar 

  49. Giralt S, Gajewski J, Khouri I et al. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia Blood 1997 90 (Suppl. 1): 1857a

    Google Scholar 

  50. Khouri I, Keating M, Korbling M et al. Transplant lite: induction of graft-versus-leukemia using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817–2824

    CAS  PubMed  Google Scholar 

  51. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  52. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 1997 89: 3048–3054

    CAS  PubMed  Google Scholar 

  53. Antin JH, Ferrara JLM . Cytokine dysregulation and acute graft-versus-host disease Blood 1992 80: 2964–2968

    CAS  PubMed  Google Scholar 

  54. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines Blood 1997 90: 3204–3213

    CAS  PubMed  Google Scholar 

  55. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myelogenous leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  56. Clift RA, Buckner CD, Appelbaum FR et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia Blood 1998 92: 1455–1456

    CAS  PubMed  Google Scholar 

  57. Goldman JM, Gale RP, Bortin MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion Ann Intern Med 1988 108: 806–814

    CAS  PubMed  Google Scholar 

  58. Mackinnon S, Barnett L, Heller G, O'Reilly RJ . Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia Blood 1994 83: 3409–3416

    CAS  PubMed  Google Scholar 

  59. Radich JP, Gehly G, Gooley T et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients Blood 1995 85: 2632–2638

    CAS  PubMed  Google Scholar 

  60. Hughes TP, Morgan GJ, Martiat P, Goldman JM . Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse Blood 1991 77: 874–878

    CAS  PubMed  Google Scholar 

  61. Pichert G, Alyea EP, Soiffer RJ et al. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia Blood 1994 84: 2109–2114

    CAS  PubMed  Google Scholar 

  62. DeLage R, Soiffer RJ, Dear K, Ritz J . Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia Blood 1991 78: 2759–2767

    CAS  PubMed  Google Scholar 

  63. Rapanotti MC, Arcese W, Buffolino S et al. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation Bone Marrow Transplant 1997 19: 703–707

    CAS  PubMed  Google Scholar 

  64. Raanani P, Dazzi F, Sohal J et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation Br J Haematol 1997 99: 945–950

    CAS  PubMed  Google Scholar 

  65. Bacigalupo A, Soracco M, Vassallo F et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation Bone Marrow Transplant 1997 19: 927–932

    CAS  PubMed  Google Scholar 

  66. Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results J Clin Oncol 1994 12: 748–758

    CAS  PubMed  Google Scholar 

  67. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201–4205

    CAS  PubMed  Google Scholar 

  68. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival has not risen because of higher treatment-related mortality – a report of 764 cases from the EBMT lymphoma registry Blood 1997 90: 255a (Abstr. 1121)

    Google Scholar 

  69. Rondón G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1996 18: 669–672

    PubMed  Google Scholar 

  70. Van Besien KW, De Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977–982

    CAS  PubMed  Google Scholar 

  71. Khouri I, Keating MJ, Przepiorka D et al. Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia Blood 1996 88 (Suppl. 1): 301a

    Google Scholar 

  72. Van Besien K, Sobocinski K, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma Blood 1998 92: 1832–1836

    CAS  PubMed  Google Scholar 

  73. Khouri IF, Przepiorka D, Van Besien K et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease Br J Haematol 1997 97: 466–473

    CAS  PubMed  Google Scholar 

  74. Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia Ann Intern Med 1996 124: 311–315

    CAS  PubMed  Google Scholar 

  75. Khouri I, Lee M-S, Palmer L et al. Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplant for low grade lymphoma Blood 1999 94 (Suppl. 1): 1553a

    Google Scholar 

  76. Khouri I, Lee M-S, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol 1999 10: 1293–1299

    CAS  PubMed  Google Scholar 

  77. Choudhury A, Gajewski J, Liang JC et al. Use of leukemic dendritic cells for the generation of anti-leukemic cellular cytotoxicity against Philadelphia chromosome positive chronic myelogenous leukemia Blood 1997 89: 1133–1142

    CAS  PubMed  Google Scholar 

  78. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease Blood 1998 91: 1083–1090

    CAS  PubMed  Google Scholar 

  79. Porter DL, Roth MS, Lee SJ et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation Bone Marrow Transplant 1996 18: 975–980

    CAS  PubMed  Google Scholar 

  80. Okumura H, Takamatsu H, Yoshida T . Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation Br J Haematol 1996 93: 386–388

    CAS  PubMed  Google Scholar 

  81. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation Blood 1997 90: 4206–4211

    CAS  PubMed  Google Scholar 

  82. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle Blood 1996 87: 1196–1198

    CAS  PubMed  Google Scholar 

  83. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease J Clin Oncol 1996 14: 572–578

    CAS  PubMed  Google Scholar 

  84. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans Bone Marrow Transplant 2000 25: 345–350

    CAS  PubMed  Google Scholar 

  85. Anderlini P, Giralt S, Ueno N et al. Allogeneic stem cell transplantation with fludarabine based less intensive conditioning as adoptive immunotherapy in advanced Hodgkin's disease Proc Am Assoc Clin Oncol 2000 19: 62a

    Google Scholar 

  86. Cardoso AA, Seamon MJ, Afonso HM et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells Blood 1997 90: 549–561

    CAS  PubMed  Google Scholar 

  87. Brenner M, Porcelli S . Antigen presentation: a balanced diet Science 1997 277: 332

    CAS  PubMed  Google Scholar 

  88. Ueno NT, Rondón G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer J Clin Oncol 1998 16: 986–993

    CAS  PubMed  Google Scholar 

  89. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer Blood 1996 88: 1501–1508

    CAS  PubMed  Google Scholar 

  90. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect J Clin Oncol 1999 17: 2044–2049

    CAS  PubMed  Google Scholar 

  91. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  92. Carella AM, Lerma E, Dejana A et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias Haematologica 1998 83: 904–909

    CAS  PubMed  Google Scholar 

  93. Storb R, Yu C, Sandmaier B et al. Mixed hematopoietic chimerism after hematopoietic stem cell allografts Transplant Proc 1999 31: 677–678

    CAS  PubMed  Google Scholar 

  94. Storb R, Yu C, Sandmaier BM et al. Mixed hematopoietic chimerism after marrow allografts – transplantation in the ambulatory care setting Ann NY Acad Sci 1999 872: 372–376

    CAS  PubMed  Google Scholar 

  95. McSweeney P, Niederwieser D, Shizuru J et al. Outpatient allografting with minimally myeosuppressive immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and mycophenolate mofetil Blood 1999 94 (Suppl. 1): 393a

    Google Scholar 

  96. Kelemen E, Masszi T, Reményi P et al. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, nonmyeloablative drug combination Bone Marrow Transplant 1998 21: 747–749

    CAS  PubMed  Google Scholar 

  97. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation Lancet 1999 353: 1755–1759

    CAS  PubMed  Google Scholar 

  98. Khoury H, Adkins D, Pence H et al. Low transplant related acute complications in patients with CML undergoing allogeneic stem cell transplantation with a low dose (550 cGy) total body irradiation conditioning regimen Blood 1999 94 (Suppl. 1): 711a

    Google Scholar 

  99. Shimoni A, Anderlini P, Andersson B et al. CD8-deplete donor lymphocyte infusion (DLI) for the treatment of CML relapse after allogeneic transplant: long-term follow-up and factors predicting outcome Blood 1999 94: 700a

    Google Scholar 

  100. Giralt S, Cohen A, Mehra R et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning Blood 1997 90: 1853a

    Google Scholar 

  101. Khouri I, Lee M-S, Palmer L et al. Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplantation for low grade lymphoma Blood 1999 94: 1553a

    Google Scholar 

  102. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 1996 88: 2787–2793

    CAS  PubMed  Google Scholar 

  103. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma J Clin Oncol 1995 13: 1312–1322

    CAS  PubMed  Google Scholar 

  104. Bertucci F, Viens P, Gravis G et al. High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution Anticancer Res 1999 19: 1455–1461

    CAS  PubMed  Google Scholar 

  105. Bacigalupo A, Vitale V, Corvò R et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation Br J Haematol 2000 108: 99–104

    CAS  PubMed  Google Scholar 

  106. Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial Blood 2000 95: 1572–1579

    CAS  PubMed  Google Scholar 

  107. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease Blood 1995 86: 1261–1268

    CAS  PubMed  Google Scholar 

  108. Rahman SL, Mahendra P, Nacheva E et al. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML Bone Marrow Transplant 1998 21: 955–956

    CAS  PubMed  Google Scholar 

  109. Dazzi F, Szydlo RM, Craddock C et al. Comparison ofsingle-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 2000 95: 67–71

    CAS  PubMed  Google Scholar 

  110. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial Transplantation 1994 57: 82–87

    CAS  PubMed  Google Scholar 

  111. Giralt S, Hester J, Huh Y et al. CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft-vs-leukemia without graft-vs-host disease Blood 1995 86: 4337–4343

    CAS  PubMed  Google Scholar 

  112. Guinan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic histoincompatible bone marrow allografts New Engl J Med 1999 340: 1704–1714

    CAS  PubMed  Google Scholar 

  113. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 1997 276: 1719–1724

    CAS  PubMed  Google Scholar 

  114. Munshi NC, Govindarajan R, Drake R et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir Blood 1997 89: 1334–1340

    CAS  PubMed  Google Scholar 

  115. Tiberghien P, Reynolds CW, Keller J et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation Blood 1994 84: 1333–1341

    CAS  PubMed  Google Scholar 

  116. Champlin R, Henslee-Downey J, Bensinger W et al. Phase I/II study of thymidine kinase (tk)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies Blood 1999 94 (Suppl. 1): 324a

    Google Scholar 

  117. Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination Blood 1994 83: 288–298

    CAS  PubMed  Google Scholar 

  118. Mavroudis DA, Dermime S, Molldrem J et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions Br J Haematol 1998 101: 565–570

    CAS  PubMed  Google Scholar 

  119. Garderet L, Snell V, Przepiorka D et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations Transplantation 1999 67: 124–130

    CAS  PubMed  Google Scholar 

  120. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation Lancet 1995 345: 9–13

    CAS  PubMed  Google Scholar 

  121. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor New Engl J Med 1995 333: 1038–1044

    CAS  PubMed  Google Scholar 

  122. Smit WM, Rijnbeek M, Van Bergen CAM et al. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay Bone Marrow Transplant 1998 21: 553–560

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Champlin, R., Khouri, I., Anderlini, P. et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 27 (Suppl 2), S13–S22 (2001). https://doi.org/10.1038/sj.bmt.1702864

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702864

Keywords

This article is cited by

Search

Quick links